Sanofi (NASDAQ:SNY) Shares Sold by Ledyard National Bank

Ledyard National Bank trimmed its holdings in Sanofi (NASDAQ:SNY) by 41.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 13,422 shares of the company’s stock after selling 9,684 shares during the quarter. Ledyard National Bank’s holdings in Sanofi were worth $647,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Synergy Asset Management LLC acquired a new position in shares of Sanofi during the 4th quarter valued at about $25,000. Northwest Investment Counselors LLC purchased a new stake in shares of Sanofi during the 3rd quarter valued at approximately $29,000. Concord Wealth Partners lifted its holdings in Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares during the last quarter. Fortitude Family Office LLC grew its position in Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares during the period. Finally, Sunbelt Securities Inc. grew its position in Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares during the period. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Down 1.2 %

Sanofi stock opened at $52.87 on Friday. The firm has a market capitalization of $134.18 billion, a P/E ratio of 21.23, a P/E/G ratio of 1.26 and a beta of 0.57. The stock’s fifty day simple moving average is $49.62 and its 200-day simple moving average is $52.35. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a current ratio of 1.46, a quick ratio of 0.74 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. As a group, equities analysts expect that Sanofi will post 4.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on SNY. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.